Mercilon (Desogestrel, Ethinylestradiol)

The combination suppresses the mid‑cycle surge of luteinising hormone and follicle‑stimulating hormone, preventing ovulation. Desogestrel thickens cervical mucus, while ethinylestradiol stabilises the endometrial lining, together creating conditions that inhibit fertilisation and implantation.

The dosing regimen for Mercilon is determined by the prescribing healthcare professional. Typically, it is taken as one tablet daily at the same time each day, but the exact schedule and duration should follow the prescriber’s instructions.

Mercilon is contraindicated during pregnancy; it should be stopped if pregnancy is confirmed. Limited data exist for use while breastfeeding, and the decision should be made by a healthcare provider weighing potential risks and benefits.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mercilon contains desogestrel, a third‑generation progestin, which is associated with a lower incidence of androgenic side effects compared with older progestins. Its efficacy in preventing pregnancy is comparable to other combined oral contraceptives, while the side‑effect profile may differ slightly based on the specific progestin used.

Mercilon tablets should be stored at ambient temperature, preferably below 25 °C, in their original packaging to protect from moisture and light. Keep the container tightly closed and out of reach of children.

Mercilon is taken orally as a tablet. The usual practice is to swallow one tablet each day, preferably at the same time each day, with or without food, following the prescriber’s schedule.

Serious risks include venous thromboembolism (deep‑vein thrombosis, pulmonary embolism), arterial events such as stroke or myocardial infarction, severe allergic reactions, and liver dysfunction. Women with a history of clotting disorders, smoking, or certain cardiovascular conditions should discuss these risks with their clinician.

Mercilon is contraindicated in women who are pregnant, have a known or suspected breast cancer, have a history of thromboembolic disorders, uncontrolled hypertension, severe liver disease, or are smokers aged 35 years or older. A thorough medical evaluation is required before initiating therapy.